Elevated Levels of Serum-Free Light Chains Linked to Increased Risk of Lymphoma in Patients With HIV: Presented at AIDS 2010
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Elevated Levels of Serum-Free Light Chains Linked to Increased Risk of Lymphoma in Patients With HIV: Presented at AIDS 2010

By Jenny Powers

VIENNA -- July 23, 2010 -- The presence of elevated levels of serum-free light chains (sFLC) are a strong and sensitive marker for the risk of patients with HIV developing non-Hodgkin's Lymphoma and Hodgkin's Disease, researchers said here at the 18th International AIDS Conference.

Furthermore, longer combined anti-retroviral treatment (ART) duration was associated with a longer period of viraemia suppression and decreased risk of developing non-Hodgkin's Lymphoma or Hodgkin's Disease.

Maria Paola Trotta, MD, Istituto Nazionale Malattie Infettive Spallanzani, Rome, Italy presented results here on July 21.

The study included patients with HIV who were also diagnosed with either non-Hodgkin's Lymphoma or Hodgkin's Disease, who were a subgroup of a case control study that enrolled 6,500 participants during a 10-year period from 1997 to 2007.

Of these patients, a total of 138 samples from 46 patients with non-Hodgkin's Lymphoma (n = 30) and Hodgkin's Disease (n = 16) were matched by sex, age, and distance from diagnosis/selection with controls.

All samples were assessed for quantitative levels of sFLC. Logistic regression was used to determine the relationship between sFLC levels and diagnosis.

The sFLC levels were significantly higher in patients with lymphoma than in controls (P =.003), making sFLC a predictive marker for the risk of non-Hodgkin's Lymphoma and Hodgkin's Disease that was statistically independent of CD4 counts.

Longer duration of suppressed viraemia (<400 copies/mL) was independently associated with decreased sFLC levels and a lower risk of lymphoma.

It was observed that patients with >50% of normal threshold at most recent sample (0-3 years) showed an increased risk of lymphoma than patients with equal levels at earlier samples dates; it was concluded that a study that included sequential sampling could define this trend.

[Presentation title: Role of Serum Free Light Chains (sFLC) in Predicting HIV-Associated Non Hodgkin's Lymphoma (NHL) and Hodgkin's Disease (HD) and Its Correlation With Effective Combined Antiretroviral Treatment (cART). Abstract TUPDB102]


E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities